Clik here to view.
Stellar Biotechnologies harvests mollusks for KLH protein
A mollusk living in the coastal waters off California from Monterey to the Baja Peninsula may hold the key to new therapies to treat cancer and autoimmune diseases. Frank Oakes Stellar Biotechnologies...
View ArticleClik here to view.
Stellar in KLH supply pact with Biovest
Stellar Biotechnologies (OTCQB:SBOTF; TSX-V:KLH) and Biovest International have executed a definitive supply agreement to meet Biovest’s requirements for Keyhole Limpet Hemocyanin (KLH) for use in its...
View ArticleClik here to view.
Stellar in KLH supply pact with Araclon
Stellar Biotechnologies (OTCQB:SBOTF; TSX-V:KLH) and Araclon Biotech have signed a definitive exclusive supply agreement to meet Araclon’s Phase 2 and 3 clinical trial requirements for Keyhole Limpet...
View ArticleClik here to view.
Maxim starts Stellar Biotechnologies at buy
Maxim Group has initiated coverage of Stellar Biotechnologies (NASDAQ:SBOT) with a “buy” rating and $17 price target. The stock closed at $7.48 on Monday. Stellar leverages its on-land aquaculture...
View Article
